Last reviewed · How we verify

Amevive — Competitive Intelligence Brief

Amevive (ALEFACEPT) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD2-directed LFA-3/Fc Fusion Protein. Area: Immunology.

marketed CD2-directed LFA-3/Fc Fusion Protein T-cell surface antigen CD2 Immunology Recombinant protein Live · refreshed every 30 min

Target snapshot

Amevive (ALEFACEPT) — Astellas Pharma.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Amevive TARGET ALEFACEPT Astellas Pharma marketed CD2-directed LFA-3/Fc Fusion Protein T-cell surface antigen CD2 2003-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD2-directed LFA-3/Fc Fusion Protein class)

  1. Astellas Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Amevive — Competitive Intelligence Brief. https://druglandscape.com/ci/alefacept. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: